Morphine (Chlorhydrate) Lavoisier (Morphine Hydrochloride)

Morphine, the active ingredient in Morphine (Chlorhydrate) Lavoisier, is an opioid analgesic presented as a sterile solution for epidural, intrathecal, and intravenous use. It provides potent analgesia for patients requiring intensive pain control in peri‑operative and palliative settings, and is employed to manage severe acute pain and chronic cancer‑related pain in adult patients.

GNH USA supplies Morphine (Chlorhydrate) Lavoisier as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies, and clinics worldwide, adhering to stringent quality standards and regulatory requirements.

Morphine is an opioid analgesic used to treat pain conditions that involve the central nervous system.

- Severe acute pain: provides rapid, strong analgesia for trauma or surgical patients. - Chronic cancer pain: offers sustained relief for malignant disease‑related discomfort. - Post‑operative pain: facilitates early mobilization by controlling surgical pain. - Palliative‑care pain: improves quality of life for patients with advanced illness.

Morphine may cause a range of adverse reactions, from mild to life‑threatening.

Common Side Effects: - Nausea: feeling of sickness often accompanied by vomiting. - Constipation: reduced bowel motility leading to hard stools. - Drowsiness: increased sleepiness or reduced alertness. - Dizziness: sensation of light‑headedness or unsteadiness. - Itching: pruritus, especially on the face or torso. - Dry mouth: reduced salivation causing discomfort.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing that can be fatal. - Severe hypotension: marked drop in blood pressure leading to fainting. - Anaphylaxis: rapid allergic reaction with airway compromise. - Dependence or addiction: development of physical or psychological reliance. - Seizures: rare occurrence of convulsive episodes. - Adrenal insufficiency: impaired cortisol production causing fatigue and weakness.

When using Morphine, clinicians should observe several safety measures.

- Assess respiratory function: monitor for depression, especially after dose changes. - Evaluate renal and hepatic function: adjust use in patients with impairment. - Avoid use in patients with known hypersensitivity to morphine or its excipients. - Use caution in the elderly: increased sensitivity to central nervous system effects. - Pregnancy and lactation: consider risk‑benefit; use only if essential. - Store below 25°C: keep in the original container, protect from light and moisture.

Morphine can interact with other medicines, altering its safety or effectiveness.

Major Interactions (Avoid): - CNS depressants (e.g., benzodiazepines, barbiturates): additive respiratory depression. - MAO inhibitors: risk of severe hypertension or serotonin syndrome. - SSRIs or SNRIs: potential for serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): increased morphine plasma concentrations. - CYP3A4 inducers (e.g., rifampin): reduced analgesic effect. - Diuretics: may enhance hypotensive response.